References
1. Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf. 2015;38(8):711-20.
2. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol.2015;35(5):1056-65.
3. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis journal. 2013;11(1):21.
4. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. Bmj.2017;359:j5058.
5. Elikowski W, Małek M, Skowroński M, Wróblewski D, Skrzywanek P, Zawilska K. [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2015;39(232):227-30.
6. Menendez D, Michel J. Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.Proceedings (Baylor University Medical Center). 2016;29(4):414-5.
7. Stöllberger C, Bastovansky A, Finsterer J. Fatal intracerebral bleeding under rivaroxaban. International journal of cardiology.2015;201:110-2.
8. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1046-55.
9. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1056-64.
10. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. Am J Nephrol. 2016;43(4):229-36.
11. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.J Pharmacol Exp Ther. 2011;338(1):372-80.
12. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66.
13. EPAR. EU Risk Management Planhttps://wwwemaeuropaeu/en/medicines/human/EPAR/xarelto.2018;[Accessed June 09, 2018].
14. FDA. XareltoXarelto (Rivaroxaban) Product Informationhttps://wwwaccessdatafdagov/drugsatfda_docs/label/2020/202439s031,022406s035lblpdf#page=60.2020;[Accessed March 01, 2020].
15. Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018;135:60-79.
16. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.Lancet. 2018;391(10117):219-29.
17. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral hemorrhage under rivaroxaban. International journal of cardiology. 2013;167(6):e179-81.
18. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor xa inhibitor–in healthy subjects. Int J Clin Pharmacol Ther. 2007;45(6):335-44.
19. Ning J, Liu T, Dong P, et al. Molecular Design Strategy to Construct the Near-Infrared Fluorescent Probe for Selectively Sensing Human Cytochrome P450 2J2. J Am Chem Soc. 2019;141(2):1126-34.
20. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.Mol Pharmacol. 2002;62(1):162-72.
21. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38(4):978-88.
22. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40(1):83-92.
23. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41.
24. Michaels S, Wang MZ. The revised human liver cytochrome P450 ”Pie”: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos.2014;42(8):1241-51.
25. Wang X, He B, Shi J, Li Q, Zhu HJ. Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions. Drug Metab Dispos.2020;48(1):31-40.
26. Sai Y, Dai R, Yang TJ, et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.Xenobiotica; the fate of foreign compounds in biological systems.2000;30(4):327-43.
27. Ching MS, Blake CL, Malek NA, Angus PW, Ghabrial H. Differential inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine.Xenobiotica; the fate of foreign compounds in biological systems.2001;31(11):757-67.
28. Naraharisetti SB, Lin YS, Rieder MJ, et al. Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos.2010;38(6):889-93.
29. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem.1996;271(7):3460-8.
30. Michaud V, Frappier M, Dumas MC, Turgeon J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism.PLoS One. 2010;5(12):e15666.
31. Delozier TC, Kissling GE, Coulter SJ, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 2007;35(4):682-8.
32. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science.1999;285(5431):1276-9.
33. Xu X, Zhang XA, Wang DW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev. 2011;63(8):597-609.
34. Cheong EJ, Goh JJ, Hong Y, et al. Application of Static Modeling –in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies. Drug Metab Dispos. 2017;45(3):260-8.
Table 1 . Kinetic parameters of rivaroxaban by HLM and selected CYPs.